Pharmacy Conferences in 2026: A Complete Guide for Healthcare Industry Leaders
For pharmaceutical leaders planning their pharmacy conferences 2026 calendar, the goal should have already moved beyond attending scientific meetings and instead center around engaging the health system executives who influence formulary decisions, site-of-care strategy, and drug adoption. As health systems have consolidated and centralized decision-making, successful pharma commercial, market access, and medical affairs teams must prioritize conferences that enable meaningful dialogue with C-suite and pharmacy leadership rather than transactional interactions.
This guide highlights the most relevant pharmacy conferences in 2026 and helps teams distinguish between events focused on scientific advancement, commercial strategy, and the closed-door executive conversations that drive real adoption outcomes within health systems.
The Best Pharmacy Conferences of 2026
THMA Pharmacy Growth Collaborative 2026
Dates and Location: Spring: June 3–5, 2026 | Carlsbad, CA Fall: October 14–16, 2026 | Boston, MA
Who It Is For: Pharma commercial, market access, and managed care leaders who need direct engagement with health system pharmacy executives governing formulary strategy, specialty drug access, 340B program management, and ambulatory infusion infrastructure.
Why It Stands Out in 2026: Health system pharmacy executives are actively rethinking formulary governance, 340B strategy, and manufacturer partnerships in response to the IRA's drug pricing provisions, Medicaid funding uncertainty, and the rapid growth of ambulatory infusion as a service line. The Pharmacy Growth Collaborative is where rethinking surfaces candid, closed-door peer conversations rather than curated conference presentations.
Best Suited For: Pharma commercial and market access teams managing specialty, oncology, or infusion-dependent portfolios where health system formulary access is a central commercial variable, and field medical teams whose launch or pull-through planning depends on validated, provider-level insight into how formulary governance is evolving at major integrated delivery systems.
THMA Oncology Forum 2026
Dates and Location: Spring: May 6–8, 2026 | Fort Lauderdale, FL Fall: September 16–18, 2026 | Boston, MA
Who It Is For: Pharma commercial leaders, oncology market access teams, and field medical executives who need direct engagement with the health system oncology leadership influencing pathway inclusion, formulary positioning, and clinical implementation.
Why It Stands Out in 2026: The FDA approval pace in oncology has outstripped health system capacity to evaluate and absorb new therapies, making pathway governance the most consequential lever in health system oncology and the executives who govern it the highest-value audience for pharma commercial strategy. The Oncology Forum places industry leaders in closed-door dialogue with Oncology Service Line Executives from Mayo Clinic, Yale New Haven Health, Northwell Health, Cleveland Clinic, Cedars-Sinai, and Mass General Brigham, among others, at a 1:1 health system-to-industry ratio.
Attending provides distinct reads on how health system oncology strategy is evolving across the year.
Best Suited For: Pharma commercial and market access teams with active or pipeline oncology portfolios where pathway governance and health system adoption are central commercial variables. The fall forum carries added relevance for organizations whose Q3 and Q4 brand planning cycles benefit from fresh executive intelligence before annual planning is finalized.
THMA Cardiovascular Forum 2026
Dates and Location: Spring: May 6–8, 2026 | Fort Lauderdale, FL Fall: September 16–18, 2026 | Boston, MA
Who It Is For: Pharma commercial leaders, cardiovascular market access teams, and medical affairs executives with marketed or pipeline cardiovascular therapies requiring alignment with the health system cardiovascular leadership governing service line strategy, formulary positioning, and site-of-care decisions.
Why It Stands Out in 2026: The cardiovascular pipeline is among the most active it has been in years, while health systems are simultaneously navigating site-neutral payment reform, ambulatory surgical center expansion, and AI-assisted care integration, all of which are reshaping the commercial environment for cardiovascular therapies in ways that field intelligence alone cannot capture. The Cardiovascular Forum convenes Cardiovascular Service Line Leaders from Mayo Clinic, Cleveland Clinic, Intermountain Health, Northwell Health, and Yale New Haven Health, among others, in a retreat-style format with a 1:1 health system-to-industry ratio. Each meeting provides a direct read from health system cardiovascular executives on where service line strategy is heading before annual brand planning is finalized, producing sharper market access and account strategy for the year ahead.
Best Suited For: Pharmaceutical and biotech companies with marketed or late-stage cardiovascular therapies whose commercial success depends on understanding and aligning with the health system executives who shape service line direction, formulary decisions, and care delivery design. Organizations managing multi-product cardiovascular franchises or sustained account relationships at major health systems will find the twice-annual cadence particularly valuable.
THMA CPE Circle 2026
Dates and Location: Spring: May 11–13, 2026 | Fort Lauderdale, FL Fall: October 26–28, 2026 | Scottsdale, AZ
Who It Is For: Pharma commercial, medical affairs, and strategic leadership teams whose formulary success or clinical pathway inclusion depends on physician executive sponsorship at the health system level.
Why It Stands Out in 2026: Chief Physician Executives govern the clinical governance infrastructure that determines whether a therapy gains traction across an independent health system's entire clinical enterprise, and they are among the most difficult executives to reach through conventional conference channels. The CPE Circle is the only executive forum built specifically around this audience, convening CPEs from major health systems twice annually at a 1:1 health system-to-industry ratio with continuing education accreditation.
Best Suited For: Pharma organizations whose commercial pathway requires physician executive sponsorship for formulary adoption or clinical protocol inclusion, particularly in therapeutic areas where physician governance plays a defining role in health system adoption decisions.
J.P. Morgan 44th Annual Healthcare Conference 2026
Dates and Location: January 12–15, 2026 | The Westin St. Francis, San Francisco, CA (This event has already taken place for 2026. It is included here for annual planning reference.)
Who It Is For: Pharmaceutical and biotech executives, investors, and business development leaders across the full breadth of the healthcare industry.
Why It Stands Out: The largest healthcare investment symposium in the world, and the primary venue for capital markets positioning, pipeline disclosure, and strategic partnership initiation at the start of the commercial year. The formal program is invitation-only through J.P. Morgan, but the surrounding week's programming is broadly accessible.
Best Suited For: Executive leadership, business development, and investor relations teams at commercial-stage and pre-launch pharma organizations.
AAOS Annual Meeting 2026
Dates and Location: March 19–23, 2026 | Las Vegas, NV
Who It Is For: Industry organizations with pharmaceutical, biologic, or device portfolios intersecting with orthopedic surgery, bone health, perioperative care, or musculoskeletal disease management.
Why It Stands Out: The largest orthopedic event in the world, drawing more than 30,000 attendees, and the primary venue for clinical evidence presentation, surgeon engagement, and competitive landscape intelligence in the musculoskeletal space.
Best Suited For: Pharma and biotech commercial and medical affairs teams with musculoskeletal, bone health, or perioperative portfolios requiring engagement with orthopedic surgical leadership and the health system service line executives governing musculoskeletal care delivery.
ACC Annual Scientific Session 2026 (ACC.26)
Dates and Location: March 28–30, 2026 | Ernest N. Morial Convention Center, New Orleans, LA
Who It Is For: Cardiologists, cardiovascular researchers, payers, health system administrators, and industry organizations with a cardiovascular commercial or pipeline presence.
Why It Stands Out: The most concentrated single gathering of cardiovascular clinical science in the United States, where late-breaking trial readouts and updated practice guidelines across heart failure, atrial fibrillation, dyslipidemia, and structural heart disease establish the clinical context for formulary and commercial conversations throughout the rest of the year.
Best Suited For: Pharma commercial, medical affairs, and market access teams with cardiovascular portfolios whose formulary and pathway strategies depend on staying current with the clinical evidence landscape as it develops.
AMCP Annual Meeting 2026
Dates and Location: April 13–16, 2026 | Music City Center, Nashville, TN
Who It Is For: Managed care pharmacy professionals, health plan and PBM decision-makers, and pharma market access and health economics teams engaged with coverage policy, formulary management, and pharmacy benefit strategy.
Why It Stands Out: The premier gathering of the managed care pharmacy community, drawing more than 4,000 professionals who govern formulary decisions, utilization management, and pharmacy benefit structure across payers and health systems. THMA attends as part of its engagement with the broader pharmacy and market access landscape.
Best Suited For: Pharma market access, health economics, and payer affairs teams navigating formulary positioning, coverage strategy, and utilization management for specialty, oncology, or complex-population products.
Asembia Specialty Pharmacy Summit 2026
Dates and Location: Late April / Early May 2026 | Las Vegas, NV (Dates to be confirmed.)
Who It Is For: Specialty pharmacy industry leaders, pharma commercial and market access teams, hub services organizations, and health system specialty pharmacy executives engaged with rare disease, oncology, immunology, and other specialty therapeutic categories.
Why It Stands Out: The leading annual gathering for the specialty pharmacy industry, drawing more than 5,000 attendees representing manufacturers, distributors, specialty pharmacies, and health system pharmacy programs, with concentrated access to the distribution, access, and operational infrastructure supporting specialty product delivery.
Best Suited For: Pharma market access, trade, and channel strategy teams managing specialty portfolio distribution, patient access programs, and hub services, as well as organizations evaluating health system specialty pharmacy partnership strategies.
LTEN Annual Conference 2026
Dates and Location: June 2026 (Location to be confirmed.)
Who It Is For: Life sciences training and enablement professionals, pharma commercial operations leaders, and field force effectiveness executives across pharmaceutical, biotech, and medical device organizations.
Why It Stands Out: The primary professional development event for learning and enablement functions within pharma and life sciences, directly relevant as health system engagement grows more sophisticated and account management at the executive level requires higher internal capability standards.
Best Suited For: Pharma commercial operations and training teams responsible for equipping account management and field medical professionals to engage health system executives at the strategic level those executives now expect.
Fierce Pharma Week 2026
Dates and Location: September 14–17, 2026 | Pennsylvania Convention Center, Philadelphia, PA
Who It Is For: Pharma commercial, marketing, medical affairs, and new product planning professionals from pharmaceutical and biotech organizations.
Why It Stands Out: The pharmaceutical industry's leading cross-functional conference for commercial and communications strategy, drawing 3,000 attendees in its inaugural 2025 run with senior representation from AbbVie, AstraZeneca, Bristol Myers Squibb, Johnson and Johnson, Pfizer, Regeneron, and Takeda, among others. The 2026 edition expands dedicated content tracks across pharma marketing, commercialization, and medical affairs.
Best Suited For: Pharma commercial, marketing, and medical affairs leadership teams who need cross-functional perspectives on launch execution, brand strategy, and omnichannel market engagement.
ACCC 43rd National Oncology Conference 2026
Dates and Location: October 21, 2026 | Omni Boston Hotel at the Seaport, Boston, MA
Who It Is For: Oncology clinicians, administrators, and program leaders from community cancer centers and hospital-based oncology programs, along with pharma and health technology organizations engaged with the community oncology setting.
Why It Stands Out: The leading interdisciplinary event for the cancer care community, organized by a network of more than 28,000 practitioners from 2,100 hospitals and practices, with a focus on the operational and clinical realities of community oncology that larger scientific conferences do not address. THMA's team attends as part of ongoing engagement with the oncology community.
Best Suited For: Pharma and health technology organizations whose oncology products or services require adoption in community cancer program settings, as well as organizations focused on access, navigation, and care delivery solutions in the cancer space.
ASHP Midyear Clinical Meeting 2026
Dates and Location: December 2026 | New Orleans, LA (Dates and venue to be confirmed.)
Who It Is For: Health-system pharmacists, pharmacy buyers, and industry organizations whose products or services intersect with hospital and health-system pharmacy operations, clinical pharmacy practice, and medication management.
Why It Stands Out: The largest pharmacy meeting in the United States, drawing more than 20,000 pharmacy professionals and providing the most concentrated single access point to the health-system pharmacy practitioners who govern day-to-day formulary implementation and medication use policy in hospital settings.
Best Suited For: Pharma commercial, market access, and medical affairs teams whose products are managed within health-system pharmacy programs and require sustained engagement with the clinical pharmacist community governing implementation and utilization.
DIA Annual Meeting 2026
Dates and Location: June 14-18, 2026 | Philadelphia, PA
Who It Is For: Regulatory affairs professionals, clinical development teams, medical affairs and pharmacovigilance leaders, and drug information specialists from pharmaceutical, biotech, and device organizations.
Why It Stands Out: The primary professional gathering for the regulatory affairs and clinical development community, providing concentrated access to regulatory science, agency perspectives, and the evolving evidence standards that govern drug approval and post-market surveillance.
Best Suited For: Pharma regulatory affairs, clinical development, and medical affairs teams managing active IND or NDA/BLA submissions, as well as organizations monitoring the regulatory environment for their therapeutic areas.
What to Look for in a Pharmacy Conference
The pharmacy conference landscape spans an unusually wide range of formats, audiences, and purposes. Applying consistent evaluation criteria before committing organizational resources to any event will reliably produce better returns than choosing brand recognition or attendance size alone.
Audience Composition and Seniority
A gathering of 200 health system pharmacy executives and formulary committee chairs discussing institutional drug adoption will consistently outperform a trade show floor of 15,000 attendees in terms of commercial relevance. Examine attendee profiles, not registration numbers, before committing budget.
Access Structure and Format
Large conferences compress interaction into brief exhibit hall encounters and scheduled meetings that produce business cards rather than insight. Events designed around structured peer dialogue, limited participant counts, and enforced health system-to-industry ratios produce measurably different commercial outcomes.
Topical Alignment With the 2026 Pharmacy Landscape
The issues commanding pharmacy executive attention in 2026, including 340B reform, IRA drug pricing provisions, biosimilar adoption, ambulatory infusion program development, and site-of-care economics, are specific and consequential. Review session topics critically rather than relying on event titles as proxies for relevance.
Dialogue Versus Broadcast
Peer-led, closed-door working sessions generate intelligence that keynotes and panel presentations cannot replicate, because the unfiltered operational and strategic realities that drive formulary and adoption decisions only surface in candid executive conversation. Events built around broadcast formats, however well-produced, cannot substitute for this.
Continuity of Relationship
A sustained relationship with the same peer group across multiple years produces compounding returns that single-event attendance cannot match. Programs that reconvene the same health system and industry executives consistently deserve proportionally more weight in recurring budget allocation than one-time conferences of comparable size.
Building a Thoughtful 2026 Pharmacy Conference Strategy
A well-constructed pharmacy conference strategy in 2026 is a deliberate allocation of time, senior talent, and budget across formats that serve different and genuinely non-interchangeable purposes. The conferences on this list each occupy a distinct position in that structure, and understanding those distinctions is the foundation of effective calendar planning.
Large clinical and scientific conferences are essential for scientific visibility, competitive intelligence, and engagement with the clinical community that translates evidence into practice. These events are where treatment guidelines shift, where clinical data reaches the practitioner audience that will implement it, and where scientific credibility is established over time. For any pharma organization with an active medical affairs function, these events belong in the annual calendar as a baseline.
Commercial and market access conferences address a second and distinct layer of organizational need, serving formulary strategy, payer alignment, channel management, and commercial execution functions that clinical conferences do not. For organizations navigating coverage decisions, specialty pharmacy distribution, or the commercial infrastructure required to move a specialty or launch-stage product, these events fill a gap that scientific gatherings cannot.
Executive forums occupy a third position that is both the least populated and, for pharma commercial organizations, frequently the most consequential. The THMA Pharmacy Growth Collaborative, Oncology Forum, Cardiovascular Forum, and CPE Circle are not substitutes for the events described above. They are complements to them, delivering something that neither large clinical conferences nor commercial gatherings are structurally capable of providing: direct, candid, sustained dialogue with the health system executives who translate scientific progress and commercial strategy into the operational decisions that determine whether a therapy is adopted, how it is positioned on formulary, and how it performs in practice. The organizations that plan deliberately across all three layers will create a sharper strategy and stronger institutional relationships than those that do not.